CN116407640B - 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物 - Google Patents

包含阿兹夫定和化疗试剂的抗肿瘤药物组合物

Info

Publication number
CN116407640B
CN116407640B CN202310201602.2A CN202310201602A CN116407640B CN 116407640 B CN116407640 B CN 116407640B CN 202310201602 A CN202310201602 A CN 202310201602A CN 116407640 B CN116407640 B CN 116407640B
Authority
CN
China
Prior art keywords
tumor
pharmaceutical composition
chemotherapeutic agent
group
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310201602.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN116407640A (zh
Inventor
李磐
贾丽敏
秦志勇
王朝阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan Genuine Biotech Co Ltd
Original Assignee
Henan Genuine Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Genuine Biotech Co Ltd filed Critical Henan Genuine Biotech Co Ltd
Priority to CN202310201602.2A priority Critical patent/CN116407640B/zh
Priority to US18/200,000 priority patent/US12268702B2/en
Priority to EP23174495.4A priority patent/EP4424316B1/en
Priority to JP2023083815A priority patent/JP2024125140A/ja
Publication of CN116407640A publication Critical patent/CN116407640A/zh
Priority to PCT/CN2024/079626 priority patent/WO2024183645A1/zh
Priority to TW113107343A priority patent/TW202435896A/zh
Priority to KR1020257033468A priority patent/KR20250167640A/ko
Application granted granted Critical
Publication of CN116407640B publication Critical patent/CN116407640B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202310201602.2A 2023-03-03 2023-03-03 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物 Active CN116407640B (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN202310201602.2A CN116407640B (zh) 2023-03-03 2023-03-03 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物
EP23174495.4A EP4424316B1 (en) 2023-03-03 2023-05-22 Antitumor pharmaceutical composition comprising azvudine and chemotherapeutic agent
JP2023083815A JP2024125140A (ja) 2023-03-03 2023-05-22 アズブジンと化学療法剤とを含む抗腫瘍医薬組成物
US18/200,000 US12268702B2 (en) 2023-03-03 2023-05-22 Antitumor pharmaceutical composition comprising azvudine and chemotherapeutic agent
PCT/CN2024/079626 WO2024183645A1 (zh) 2023-03-03 2024-03-01 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物
TW113107343A TW202435896A (zh) 2023-03-03 2024-03-01 包含阿茲夫定和化療試劑的抗腫瘤藥物組合物
KR1020257033468A KR20250167640A (ko) 2023-03-03 2024-03-01 아즈부딘 및 화학요법제를 포함한 항종양 약학적 조성물

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310201602.2A CN116407640B (zh) 2023-03-03 2023-03-03 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物

Publications (2)

Publication Number Publication Date
CN116407640A CN116407640A (zh) 2023-07-11
CN116407640B true CN116407640B (zh) 2025-10-31

Family

ID=86497784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310201602.2A Active CN116407640B (zh) 2023-03-03 2023-03-03 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物

Country Status (7)

Country Link
US (1) US12268702B2 (https=)
EP (1) EP4424316B1 (https=)
JP (1) JP2024125140A (https=)
KR (1) KR20250167640A (https=)
CN (1) CN116407640B (https=)
TW (1) TW202435896A (https=)
WO (1) WO2024183645A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116407640B (zh) * 2023-03-03 2025-10-31 河南真实生物科技有限公司 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物
CN116196325A (zh) * 2023-03-10 2023-06-02 河南真实生物科技有限公司 包含阿兹夫定的免疫调节剂组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102000103B (zh) * 2009-12-21 2011-12-21 郑州大学 2’-氟-4’-叠氮-核苷类似物或其盐的药物应用
WO2021209563A1 (en) * 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2201296T3 (es) * 1996-04-26 2004-03-16 Genaera Corporation Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores.
CA2873112A1 (en) * 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
JP6878417B2 (ja) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド 剤形およびそれらの使用
EP3508205B1 (en) * 2016-08-31 2022-05-18 FUJIFILM Corporation Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit
WO2020001475A1 (en) * 2018-06-29 2020-01-02 Shanghai Changchengyiyaokeji Company Limited Phosphorus-containing prodrugs of gemcitabine
WO2020142629A1 (en) * 2019-01-02 2020-07-09 The General Hospital Corporation Reverse transcriptase blocking agents and methods of using the same
WO2021209740A1 (en) * 2020-04-16 2021-10-21 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
TW202228724A (zh) * 2020-09-23 2022-08-01 美商昂克萊亞製藥公司 以反轉錄酶抑制劑治療癌症之方法
CN116407640B (zh) * 2023-03-03 2025-10-31 河南真实生物科技有限公司 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102000103B (zh) * 2009-12-21 2011-12-21 郑州大学 2’-氟-4’-叠氮-核苷类似物或其盐的药物应用
WO2021209563A1 (en) * 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Also Published As

Publication number Publication date
EP4424316A1 (en) 2024-09-04
US12268702B2 (en) 2025-04-08
CN116407640A (zh) 2023-07-11
US20240293438A1 (en) 2024-09-05
TW202435896A (zh) 2024-09-16
EP4424316C0 (en) 2025-07-02
EP4424316B1 (en) 2025-07-02
WO2024183645A1 (zh) 2024-09-12
JP2024125140A (ja) 2024-09-13
KR20250167640A (ko) 2025-12-01

Similar Documents

Publication Publication Date Title
CN100490817C (zh) 抗肿瘤吲哚并吡咯并咔唑衍生物和其它抗肿瘤药物联合用药
CN116407640B (zh) 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物
RU2429838C2 (ru) Комбинированная химиотерапия
CN111558044B (zh) 一种包含舒尼替尼的药物组合物及其制剂和应用
BG107843A (bg) Ефективно антитуморно лечение
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
KR20140079831A (ko) 췌장암 및／또는 담도암 치료약
CN113301895A (zh) 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途
WO1994005299A1 (fr) Compositions medicinales
KR20250166964A (ko) 아즈부딘을 포함한 항종양 약학적 조성물
TWI726133B (zh) 基於癌細胞之代謝特異性之新穎抗惡性腫瘤劑
KR20200112886A (ko) 암 환자의 치료에 유용한 오줌의 알칼리제
ES2280259T3 (es) Complejos de galio de 3-hidroxi-4-pironas para tratar infecciones por procariotas intracelulares, virus de adn y retrovirus.
MXPA04006822A (es) Combinaciones que comprenden epotilonas y anti-metabolitos.
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
JP7381115B2 (ja) 組成物及びがん治療用医薬品の調製におけるその応用
CN117243963B (zh) Remodelin与Venetoclax在治疗癌症中的应用
JP6895688B2 (ja) 血液がんの新規治療法及び新規治療剤
CN108503676B (zh) 用于癌症治疗的果糖类似物及其组合物
CN114984015A (zh) 治疗增殖性疾病的联用药物组合物
CN107921134B (zh) 肿瘤基因甲基化调节剂的新用途及抗肿瘤药物
CN121285550A (zh) 一种吡咯并[2,3-c]吡啶酮化合物的联用药物组合物及其用途
WO2025247377A1 (zh) 亚氨基砜类化合物治疗淋巴瘤的用途
WO2022014025A1 (ja) 血液がんの新規治療法及び新規治療剤
HK40061085A (en) Novel therapeutic method and novel therapeutic agent for hematological cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant